Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
1.193 EUR | +1.32% |
|
-9.97% | -87.43% |
07-01 | Pacific Biosciences of California, Inc.(NasdaqGS:PACB) dropped from Russell 2500 Growth Index | CI |
06-27 | PacBio, Form Bio Team Up to Launch Initiatives to Unify AAV Gene Therapy Industry | MT |
Evolution of the average Target Price on Pacific Biosciences of California, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
![Consensus](/images/consensus_flch.gif)
Consensus detail
Consensus revision (last 18 months)
Analysts covering Pacific Biosciences of California, Inc.
Jefferies & Co. | |
Morgan Stanley | |
Piper Sandler | |
JPMorgan Chase | |
Scotiabank | |
Goldman Sachs | |
TD Cowen | |
UBS | |
Guggenheim | |
Cantor Fitzgerald | |
Barclays | |
Bernstein | |
Canaccord Genuity | |
J.P. Morgan Chase |
EPS Revisions
- Stock Market
- Equities
- PACB Stock
- P09 Stock
- Consensus Pacific Biosciences of California, Inc.